Kalaris Therapeutics, Inc.
KLRS
$3.41
-$0.06-1.73%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -6.07% | -8.58% | 15.94% | -4.79% | -11.32% |
| Total Depreciation and Amortization | 0.00% | 0.00% | 233.33% | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -100.00% |
| Total Other Non-Cash Items | 42.54% | 593.10% | -89.77% | -4.06% | 165.02% |
| Change in Net Operating Assets | 89.97% | -139.58% | 32,022.22% | 99.49% | -175.87% |
| Cash from Operations | 4.62% | -64.11% | 37.73% | 9.62% | -68.51% |
| Capital Expenditure | -- | -- | 90.71% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 140.06% | -435.67% | 143.45% | -- | -- |
| Cash from Investing | 140.06% | -436.05% | 143.17% | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -100.00% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -86.49% | -99.82% | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 78.12% | -130.82% | -- | -- | -100.00% |
| Cash from Financing | 77.76% | -103.55% | -- | -- | -100.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 113.75% | -214.30% | 220.91% | -267.17% | -112.56% |